Article Sidebar

PDF (Tiếng Việt)
Published: 2023-01-10
Abstract Views: 445
Views PDF (Tiếng Việt): 282
DOI: https://doi.org/10.52852/tcncyh.v160i12V1.1110
Issue
Vol. 160 No. 12V1 (2022)
Section
Các bài báo
How to Cite
Khánh, N. N. ., Thành, N. T. ., & Dũng, V. C. . (2023). 17. Current status of spinal muscular atrophy at the Vietnam National Children’s Hospital for 6 years 2016 - 2021 . Journal of Medical Research, 160(12V1), 121-126. https://doi.org/10.52852/tcncyh.v160i12V1.1110

17. Current status of spinal muscular atrophy at the Vietnam National Children’s Hospital for 6 years 2016 - 2021

Nguyen Ngoc Khanh, Nguyen Trong Thanh, Vu Chi Dung

Main Article Content

Abstract

Spinal Muscular Atrophy (SMA) is a neuromuscular disease characterized by progressive symmetric proximal muscle weakness and hypotonia. This a descriptive study on distribution, characteristics of phenotype and natural history of SMA in 5 years at the National Children's Hospital. 191 SMA patients were distributed as 66 (34.6%) type I, 86 (45.1%) type II and 39 (20.3%) type III. 42 (22%) children had a sibling with SMA. The diagnosed age of types I, II and III are 4.5 months, 2 years and 5.5 years, respectively. Progression of SMA type I was the most severe: 87.2% died at medium age of 10.5 months from pneumonia and respiratory failure, 53% SMA type III needed assisted sitting, 56.4% SMA type III cannot walk. The scoliosis rate of SMA type I, II and III were 75%, 74% and 56%, respectively. Conclusion: The most common SMA is type II, followed by type I, type III. The progression of SMA type I was the worst. The scoliosis and motor degeneration were the most common complications.

Article Details

Keywords

Spinal Muscular Atrophy, SMA, SMN gene

References

1. Ogino S, Wilson RB, Gold B. New insights on the evolution of the SMN1 and SMN2 region: Simulation and meta-analysis for allele and haplotype frequency calculations. Eur J Hum Genet. 2004;12(12):1015-1023.
2. Prior TW, Nagan N. Spinal muscular atrophy: Overview of molecular diagnostic approaches. Curr Protoc Hum Genet. 2016;88:9.27.1-9.27.13.
3. Kolb SJ, Kissel JT. Spinal muscular atrophy. Neurol Clin. 2015;33(4):831-846.
4. Farrar MA, Kiernan MC. The genetics of spinal muscular atrophy: Progress and challenges. Neurotherapeutics. 2015;12(2):290-302.
5. Ross LF, Kwon JM. Spinal muscular atrophy: Past, present, and future. Neoreviews. 2019;20(8):e437-e451.
6. Schorling DC, Pechmann A, Kirschner J. Advances in treatment of spinal muscular atrophy - New phenotypes, new challenges, new implications for care. J Neuromuscul Dis. 2020;7(1):1-13.
7. Albrechtsen SS, Born AP, Boesen MS. Nusinersen treatment of spinal muscular atrophy - A systematic review. Dan Med J. 2020;67(9).
8. Hoy SM. Onasemnogene abeparvovec: First global approval. Drugs. 2019;79(11):1255-1262.
9. Waldrop MA, Elsheikh BH. Spinal muscular atrophy in the treatment Era. Neurol Clin. 2020;38(3):505-518.
10. Williams L. Spinal muscular atrophy in the age of gene therapy. AACN Adv Crit Care. 2020;31(1):86-91.
11. Nguyễn Ngọc Khánh. Nghiên cứu đặc điểm lâm sàng và xét nghiệm trong chẩn đoán bệnh SMA. Luận văn Thạc sỹ Y học, Trường Đại học Y Hà Nội; 2005.
12. D’Amico A, Mercuri E, Tiziano FD, Bertini E. Spinal muscular atrophy. Orphanet J Rare Dis. 2011;6:71.
13. Wang CH, Finkel RS, Bertini ES, et al. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol. 2007;22(8):1027-1049.